霧化器與霧化參數_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

周小建 ,  洪建國

上海交通大學附屬第一人民醫院兒內科（上海 200080）;

Corresponding?author：

洪建國, Email: hongjianguo@hotmail.com

Keywords：

DOI：

10.7507/1671-6205.201808039

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 周小建, 洪建國. 霧化器與霧化參數. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(1): 98-102. doi: 10.7507/1671-6205.201808039 Copy

1.	洪建國, 王乃禮. 哮喘的吸入治療和吸入裝置. 臨床兒科雜志, 2000, 18(3): 185-186.
2.	Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J, 2008, 31(1): 143-178.
3.	中華醫學會兒科學分會呼吸學組. 兒童支氣管哮喘防治常規(試行). 中華兒科雜志, 2004, 42(2): 100-106.
4.	中華醫學會兒科學分會呼吸學組. 兒童支氣管哮喘診斷與防治指南(2016 年版). 中華兒科雜志, 2016, 54(3): 167-181.
5.	蘇遠力, 鄭勁平, 高怡. 我國醫院使用霧化吸入治療狀況的問卷調查和分析. 中華結核和呼吸雜志, 2010, 33(2): 140-141.
6.	孟海艷, 顧穎, 崔曉莉. ICU 霧化吸入技術應用現狀調查及分析. 齊齊哈爾醫學院學報, 2012, 33(21): 2991-2993.
7.	洪建國. 進一步規范兒童霧化吸入治療. 中國實用兒科雜志, 2016, 31(12): 881-883.
8.	中華醫學會呼吸病學分會《霧化吸入療法在呼吸疾病中的應用專家共識》制定專家組. 霧化吸入療法在呼吸疾病中的應用專家共識. 中華醫學雜志, 2016, 96(34): 2696-2708.
9.	Gardenhire DS, Ari A, Hess D, et al. A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4^th Edition. American Association for Respiratory Care, 2017.
10.	洪建國, 陳強, 陳志敏, 等. 兒童常見呼吸道疾病霧化吸入治療專家共識. 中國實用兒科雜志, 2012, 27(4): 265-269.
11.	Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv, 2015, 12(6): 889-900.
12.	Pritchard JN. Nebulized drug delivery in respiratory medicine: what does the future hold?. Ther Deliv, 2017, 8(6): 391-399.
13.	Arulmuthu ER, Williams DJ, Baldascini H, et al. Studies on aerosol delivery of plasmid DNA using a mesh nebulizer. Biotechnol Bioeng, 2007, 98(5): 939-955.
14.	Griese M, Scheuch G. Delivery of alpha-1 antitrypsin to airways. Ann Am Thorac Soc, 2016, (13 Suppl 4): S346-S351.
15.	Galindo-Filho VC, Ramos ME, Rattes CS, et al. Radioaerosol pulmonary deposition using mesh and jet nebulizers during noninvasive ventilation in healthy subjects. Respir Care, 2015, 60(9): 1238-1246.
16.	ElHansy MHE, Boules ME, El Essawy AFM, et al. Inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during invasive mechanical ventilation. Pulm Pharmacol Ther, 2017, 45: 159-163.
17.	Elhissi AM, Faizi M, Naji WF, et al. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm, 2007, 334(1-2): 62-70.
18.	趙德育. 不同霧化吸入裝置特點及使用要點. 中國實用兒科雜志, 2016, 31(12): 895-898.
19.	Nikander K, von Hollen D, Larhrib H. The size and behavior of the human upper airway during inhalation of aerosols. Expert Opin Drug Deliv, 2017, 14(5): 621-630.
20.	Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm, 2010, 392(1-2): 1-19.
21.	Jaafar-Maalej C, Andrieu V, Elaissari A, et al. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv, 2009, 6(9): 941-959.
22.	Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med, 2014, 2(6): 497-506.
23.	Tsuda A, Henry FS, Butler JP. Particle transport and deposition: basic physics of particle kinetics. Compr Physio, 2013, 3(4): 1437-1471.
24.	中華醫學會呼吸病學分會呼吸治療學組. 霧化治療專家共識(草案). 中華結核和呼吸雜志, 2014, 37(11): 805-808.
25.	Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med, 2014, 108(8): 1195-1203.
26.	Sheth P, Stein SW, Myrdal PB. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Int J Pharm, 2013, 455(1-2): 57-65.
27.	Geller DE, Eigen H, Fiel SB, et al. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol, 1998, 25(2): 83-87.
28.	Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol, 1996, 21(5): 276-281.
29.	Schüepp KG, Devadson S, Roller C, et al. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly, 2004, 134(13-14): 198-200.
30.	K?hler E, Jilg G, Avenarius S, et al. Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed, 2008, 93(4): F275-F279.
31.	Janssens HM, De Jongste JC, Hop WC, et al. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest, 2003, 123(6): 2083-2088.
32.	Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech, 2014, 15(2): 434-455.
33.	朱俊, 陳保壘, 盧嘉彤, 等. 不同噴射霧化器對吸入混懸液體外沉積性質的影響. 國際藥學研究雜志, 2016, 43(6): 1140-1144.
34.	Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation therapy. J Pharm Pharmacol, 2016, 68(5): 556-578.
35.	Hussein RRS, M A Ali A, Salem HF, et al. In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients. Pharm Dev Technol, 2017, 22(7): 871-880.
36.	Svartengren K, Lindestad PA, Svartengren M, et al. Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J, 1994, 7(8): 1467-1473.
37.	Svartengren K, Lindestad P, Svartengren M, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med, 1995, 152(1): 32-37.
38.	Nikander K, Prince I, Coughlin S, et al. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of ^99mTc-DTPA. J Aerosol Med Pulm Drug Deliv, 2010, 23 Suppl 1: S37-S43.
39.	van Velzen AJ, Uges JW, Le Brun PP, et al. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis. J Cyst Fibros, 2015, 14(6): 748-754.
40.	成人慢性氣道疾病霧化吸入治療專家組. 成人慢性氣道疾病霧化吸入治療專家共識. 中國呼吸與危重監護雜志, 2012, 11(2): 105-110.

1. 洪建國, 王乃禮. 哮喘的吸入治療和吸入裝置. 臨床兒科雜志, 2000, 18(3): 185-186.
2. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J, 2008, 31(1): 143-178.
3. 中華醫學會兒科學分會呼吸學組. 兒童支氣管哮喘防治常規(試行). 中華兒科雜志, 2004, 42(2): 100-106.
4. 中華醫學會兒科學分會呼吸學組. 兒童支氣管哮喘診斷與防治指南(2016 年版). 中華兒科雜志, 2016, 54(3): 167-181.
5. 蘇遠力, 鄭勁平, 高怡. 我國醫院使用霧化吸入治療狀況的問卷調查和分析. 中華結核和呼吸雜志, 2010, 33(2): 140-141.
6. 孟海艷, 顧穎, 崔曉莉. ICU 霧化吸入技術應用現狀調查及分析. 齊齊哈爾醫學院學報, 2012, 33(21): 2991-2993.
7. 洪建國. 進一步規范兒童霧化吸入治療. 中國實用兒科雜志, 2016, 31(12): 881-883.
8. 中華醫學會呼吸病學分會《霧化吸入療法在呼吸疾病中的應用專家共識》制定專家組. 霧化吸入療法在呼吸疾病中的應用專家共識. 中華醫學雜志, 2016, 96(34): 2696-2708.
9. Gardenhire DS, Ari A, Hess D, et al. A Guide to Aerosol Delivery Devices for Respiratory Therapists, 4^th Edition. American Association for Respiratory Care, 2017.
10. 洪建國, 陳強, 陳志敏, 等. 兒童常見呼吸道疾病霧化吸入治療專家共識. 中國實用兒科雜志, 2012, 27(4): 265-269.
11. Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv, 2015, 12(6): 889-900.
12. Pritchard JN. Nebulized drug delivery in respiratory medicine: what does the future hold?. Ther Deliv, 2017, 8(6): 391-399.
13. Arulmuthu ER, Williams DJ, Baldascini H, et al. Studies on aerosol delivery of plasmid DNA using a mesh nebulizer. Biotechnol Bioeng, 2007, 98(5): 939-955.
14. Griese M, Scheuch G. Delivery of alpha-1 antitrypsin to airways. Ann Am Thorac Soc, 2016, (13 Suppl 4): S346-S351.
15. Galindo-Filho VC, Ramos ME, Rattes CS, et al. Radioaerosol pulmonary deposition using mesh and jet nebulizers during noninvasive ventilation in healthy subjects. Respir Care, 2015, 60(9): 1238-1246.
16. ElHansy MHE, Boules ME, El Essawy AFM, et al. Inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during invasive mechanical ventilation. Pulm Pharmacol Ther, 2017, 45: 159-163.
17. Elhissi AM, Faizi M, Naji WF, et al. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm, 2007, 334(1-2): 62-70.
18. 趙德育. 不同霧化吸入裝置特點及使用要點. 中國實用兒科雜志, 2016, 31(12): 895-898.
19. Nikander K, von Hollen D, Larhrib H. The size and behavior of the human upper airway during inhalation of aerosols. Expert Opin Drug Deliv, 2017, 14(5): 621-630.
20. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm, 2010, 392(1-2): 1-19.
21. Jaafar-Maalej C, Andrieu V, Elaissari A, et al. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin Drug Deliv, 2009, 6(9): 941-959.
22. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med, 2014, 2(6): 497-506.
23. Tsuda A, Henry FS, Butler JP. Particle transport and deposition: basic physics of particle kinetics. Compr Physio, 2013, 3(4): 1437-1471.
24. 中華醫學會呼吸病學分會呼吸治療學組. 霧化治療專家共識(草案). 中華結核和呼吸雜志, 2014, 37(11): 805-808.
25. Demoly P, Hagedoorn P, de Boer AH, et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med, 2014, 108(8): 1195-1203.
26. Sheth P, Stein SW, Myrdal PB. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers. Int J Pharm, 2013, 455(1-2): 57-65.
27. Geller DE, Eigen H, Fiel SB, et al. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group. Pediatr Pulmonol, 1998, 25(2): 83-87.
28. Mallol J, Rattray S, Walker G, et al. Aerosol deposition in infants with cystic fibrosis. Pediatr Pulmonol, 1996, 21(5): 276-281.
29. Schüepp KG, Devadson S, Roller C, et al. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly, 2004, 134(13-14): 198-200.
30. K?hler E, Jilg G, Avenarius S, et al. Lung deposition after inhalation with various nebulisers in preterm infants. Arch Dis Child Fetal Neonatal Ed, 2008, 93(4): F275-F279.
31. Janssens HM, De Jongste JC, Hop WC, et al. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest, 2003, 123(6): 2083-2088.
32. Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech, 2014, 15(2): 434-455.
33. 朱俊, 陳保壘, 盧嘉彤, 等. 不同噴射霧化器對吸入混懸液體外沉積性質的影響. 國際藥學研究雜志, 2016, 43(6): 1140-1144.
34. Carvalho TC, McConville JT. The function and performance of aqueous aerosol devices for inhalation therapy. J Pharm Pharmacol, 2016, 68(5): 556-578.
35. Hussein RRS, M A Ali A, Salem HF, et al. In vitro/in vivo correlation and modeling of emitted dose and lung deposition of inhaled salbutamol from metered dose inhalers with different types of spacers in noninvasively ventilated patients. Pharm Dev Technol, 2017, 22(7): 871-880.
36. Svartengren K, Lindestad PA, Svartengren M, et al. Deposition of inhaled particles in the mouth and throat of asthmatic subjects. Eur Respir J, 1994, 7(8): 1467-1473.
37. Svartengren K, Lindestad P, Svartengren M, et al. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med, 1995, 152(1): 32-37.
38. Nikander K, Prince I, Coughlin S, et al. Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of ^99mTc-DTPA. J Aerosol Med Pulm Drug Deliv, 2010, 23 Suppl 1: S37-S43.
39. van Velzen AJ, Uges JW, Le Brun PP, et al. The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis. J Cyst Fibros, 2015, 14(6): 748-754.
40. 成人慢性氣道疾病霧化吸入治療專家組. 成人慢性氣道疾病霧化吸入治療專家共識. 中國呼吸與危重監護雜志, 2012, 11(2): 105-110.

Previous Article
肺部超聲評分在呼吸重癥疾病中的應用

Chinese Journal of Respiratory and Critical Care Medicine

霧化器與霧化參數

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content